There are grounds for optimism for vaccines against meningococcus group B and Professor Cartwright describes their development in slides 27-32. (associated thumbnails numbered slides 27-32)
Finally, Professor Cartwright closes his lecture by summarizing in slide 33 the current UK strategic priorities for meningitis and meningococcal disease.
